临床试验/NCT04690062

NCT04690062Unknown4 期

Brolucizumab-dbll (BEOVU®) Intravitreal Injection in the Treatment of Dystrophy-related Macular Neovascular Degeneration

Benha University1 个研究点分布在 1 个国家目标入组 20 人开始时间: 2020年10月25日最近更新: 2020年12月30日

适应症

干预措施

试验速览

阶段: 4 期
发起方: Benha University
入组人数: 20
试验地点: 1
主要终点: Best corrected visual acuity (BCVA)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Dystrophy-Related macular neovascularization degeneration occur is a vision threatening condition.The investigators evaluate the efficacy of BEOVU intravitreal treatment.

详细描述

Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done.

Procedure included intravitreal injection of Brolucizumab (BEOVU®, Genen-tech, South Francisco, CA)

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 50 Years（Adult）
性别: All
接受健康志愿者: 否

入选标准

•Dystrophy-Related macular neovascularization degeneration

排除标准

•age related macular degeneration , other causes of macular neovascularization degeneration

研究组 & 干预措施

BEOVU

Experimental

Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months

干预措施: Brolucizumab-Dbll (Drug)

结局指标

主要结局

Best corrected visual acuity (BCVA)

时间窗: 12 months

Change in BCVA in LOG MARS(logarithm minimum angle of resolution)

次要结局

optical coherence tomography (OCT) foveal thickness(12 months)

研究者

发起方

Benha University

申办方类型

Other

责任方

Principal Investigator

主要研究者

Tarek Roshdy mohamed Mahgoub ELhamaky

Lecturer of ophthalmology

Benha University

研究点 (1)

Loading locations...

相似试验

Unknown

3 期

BEOVU Versus Eylea in the Treatment of Diabetic Macular EdemaMacular Edema

NCT04955171Benha University60

Unknown

不适用

BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular DegenerationMacula Lutea Degeneration

NCT04882956Benha University40

撤回

不适用

Combination Therapy for Neovascular Age Related Macular DegenerationMacular Degeneration

NCT00447031Yonsei University

终止

4 期

Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to AfliberceptNeovascular Age-related Macular Degeneration

NCT04287348Vista Klinik16

撤回

3 期

Intravitreal Bevacizumab for Inflammatory Neovascular MembranesVogt Koyanagi Harada DiseaseSerpiginous ChoroiditisMultifocal Choroiditis

NCT00407121Asociación para Evitar la Ceguera en México